Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | SVP, CFO & Treasurer | March 26, 2021 | March 30, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director · SECRETARY AND TREASURER | March 14, 2019 | March 14, 2019 |
| Verastem, Inc.VSTM · Entity 5242 | Director | June 28, 2021 | June 30, 2021 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Financial Officer | February 01, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
IRONWOOD PHARMACEUTICALS INC
Report date March 26, 2021 · Filed March 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 392,616 |
Reported balance
After 2021-03-26 transaction · row 1
1 source rowRow 1 · 2021-03-26 · Grant · Acquired 56,372 · Balance 392,616 F1: The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023.
Korsana Biosciences, Inc.
Report date March 14, 2019 · Filed March 14, 2019
This filing explicitly reported no securities owned.
Verastem, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2031-06-28 | Direct | 25,000 |
Reported balance
After 2021-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-28 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date.
bluebird bio, Inc.
Report date February 01, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,385 |
Reported balance
After 2022-02-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-01 · Grant · Acquired 25,000 · Balance 125,385 F1: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2023, 25% on 01/04/2024, 25% on 01/04/2025, and 25% on 01/04/2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2032-02-01 | Direct | 50,000 |
Reported balance
After 2022-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-01 · Grant · Acquired 50,000 · Balance 50,000 F2: This stock option vests over a four-year period at the rate of 25% on 01/04/2023 and then in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2023, 25% on 01/04/2024, 25% on 01/04/2025, and 25% on 01/04/2026.
F2: This stock option vests over a four-year period at the rate of 25% on 01/04/2023 and then in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:35 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-259742 · ownership.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $15.81 | $0.00 |
DisclosureSEC source: 0000950170-25-083693 · ownership.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $15.06 | $0.00 |
DisclosureSEC source: 0000950170-24-066584 · ownership.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2034-05-29 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 29, 2025 and (2) the date of the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001209191-23-032867 · doc4.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2024 and (2) the date of the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:29 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-22-032555 · doc4.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001562180-22-001085 · primarydocument.xml · derivative · entry 2 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-01 F2 · derivative.exercise_date: This stock option vests over a four-year period at the rate of 25% on 01/04/2023 and then in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 18:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001085 · primarydocument.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,385 F1 · security: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2023, 25% on 01/04/2024, 25% on 01/04/2025, and 25% on 01/04/2026. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:29 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 170,655 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-21-023462 · wf-form4_163706207928299.xml · derivative · entry 2 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,655 Underlying: Common Stock · 170,655 shares Expires 2031-09-01 F4 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 1, 2021 and vests over a four-year period at the rate of 25% on August 2, 2022 and then in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 1, 2021 and vests over a four-year period at the rate of 25% on August 2, 2022 and then in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 1, 2021 and vests over a four-year period at the rate of 25% on August 2, 2022 and then in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:29 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 100,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023462 · wf-form4_163706207928299.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,385 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 1, 2021 and vests over a four-year period at the rate of 25% on August 2, 2022, 25% on August 2, 2023, 25% on August 2, 2024 and 25% on August 2, 2025. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:59 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001104659-21-087402 · tm2121071-4_4seq1.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:56 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-21-035371 · doc4.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 56,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023572 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,616 F1 · kind: The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,980 | $9.11 | $63,587.80 |
DisclosureSEC source: 0001209191-21-016018 · doc4.xml · nonDerivative · entry 4 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,244 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,242 | $9.11 | $56,864.62 |
DisclosureSEC source: 0001209191-21-016018 · doc4.xml · nonDerivative · entry 3 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,224 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,527 | $9.11 | $23,020.97 |
DisclosureSEC source: 0001209191-21-016018 · doc4.xml · nonDerivative · entry 2 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,466 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,657 | $9.11 | $24,205.27 |
DisclosureSEC source: 0001209191-21-016018 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,993 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 84,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013741 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,650 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 590 | $10.92 | $6,442.80 |
DisclosureSEC source: 0001209191-20-057600 · doc4.xml · nonDerivative · entry 2 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,699 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 2, 2018. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:03 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 825 | $10.92 | $9,009.00 |
DisclosureSEC source: 0001209191-20-057600 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,289 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16, 2016. Read SEC document |
| October 19, 2020 Filed Oct 21, 2020 21:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0001209191-20-055491 · doc4.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-19 F1 · derivative.exercise_date: Grant of stock options. The stock options vest in three approximately equal installments, assuming continuous service on each vesting date, as follows: October 19, 2021; October 19, 2022; and October 19, 2023. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:27 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 35,342 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000904454-20-000402 · edgar.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,342 Underlying: Common Stock · 35,342 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 68,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014402 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,114 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,181 | $11.63 | $71,885.03 |
DisclosureSEC source: 0001209191-20-012474 · doc4.xml · nonDerivative · entry 4 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,787 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,558 | $11.63 | $29,749.54 |
DisclosureSEC source: 0001209191-20-012474 · doc4.xml · nonDerivative · entry 3 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,968 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,252 | $11.63 | $26,190.76 |
DisclosureSEC source: 0001209191-20-012474 · doc4.xml · nonDerivative · entry 2 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,526 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,510 | $11.63 | $17,561.30 |
DisclosureSEC source: 0001209191-20-012474 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,778 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 41,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061129 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,288 F1 · kind: The restricted stock units, granted as a special retention award, vest as to 100% of the shares of Class A Common Stock on November 18, 2021. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 23:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 630 | $11.00 | $6,930.00 |
DisclosureSEC source: 0001209191-19-056188 · doc4.xml · nonDerivative · entry 2 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,138 F2 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 2, 2018. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 23:23 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 880 | $11.00 | $9,680.00 |
DisclosureSEC source: 0001209191-19-056188 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,768 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16, 2016. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 212 | $9.04 | $1,916.48 |
DisclosureSEC source: 0001209191-19-046846 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,648 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on September 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.94 to $9.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:50 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 5,137 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-19-037505 · a4.xml · derivative · entry 1 Consylman Gina · CIK 0001546358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,137 Underlying: Common Stock · 5,137 shares Expires 2029-06-21 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 4,055 | $10.53 | $42,699.15 |
DisclosureSEC source: 0001209191-19-029596 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,860 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on July 31, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 16,804 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 7 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,804 Underlying: Class A Common Stock · 16,804 shares Expires 2029-01-29 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,099 | Not disclosed Strike: $12.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 6 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,099 Underlying: Class A Common Stock · 5,099 shares Expires 2028-02-21 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,236 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 5 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Class A Common Stock · 1,236 shares Expires 2028-01-02 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F6 · derivative.exercise_date: The option, granted as a promotion award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of November 27, 2017. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 695 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 4 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,695 Underlying: Class A Common Stock · 695 shares Expires 2026-03-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77 | Not disclosed Strike: $10.20 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 3 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 Underlying: Class A Common Stock · 77 shares Expires 2025-09-16 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4 · derivative.exercise_date: The option vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of September 16, 2015. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,563 | Not disclosed Strike: $13.78 | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · derivative · entry 2 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,563 Underlying: Class A Common Stock · 3,563 shares Expires 2024-07-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F3 · derivative.exercise_date: This option, granted as a new hire award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,731 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023430 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,915 F1 · price: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 16,731 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 18 | $14.32 | $257.76 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 8 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,184 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 17 | $14.32 | $243.44 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 7 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,202 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 9 | $14.32 | $128.88 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 6 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,219 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2 | $14.32 | $28.64 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 5 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,228 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,237 | $14.31 | $32,011.47 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 4 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,230 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,957 | $14.31 | $28,004.67 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 3 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,467 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,119 | $14.31 | $16,012.89 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 2 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,424 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 318 | $14.31 | $4,550.58 |
DisclosureSEC source: 0001209191-19-012630 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,543 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 145,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006220 · doc4.xml · derivative · entry 2 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Class A Common Stock · 145,000 shares Expires 2029-01-29 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 72,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006220 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,861 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 02:41 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,358 | $11.81 | $16,037.98 |
DisclosureSEC source: 0001209191-18-058419 · doc4.xml · nonDerivative · entry 1 Consylman Gina · CIK 0001546358 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,361 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on each of December 16, 2016 and January 2, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $12.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.